Beneficial Effect of Xanthohumol Supplementation on the Clinical Course of IgA Nephropathy Refractory to Conventional Treatment—A Prospective, Open‐Label Case Series
Molecular Nutrition & Food Research · 2026-03 · 70 (6)
DOI: 10.1002/mnfr.70439 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Nutrition & Food Research, online erschienen am 12.03.2026. Verfasst von Andrzej Jaroszyński und 4 weiteren Autor:innen. Beteiligte Einrichtung: Collegium Medicum, Department of Internal Medicine and Family Medicine, Jan Kochanowski University in Kielce, Kielce, Poland. Hauptthemen laut MEDLINE: Propiophenones, Glomerulonephritis, IGA, Flavonoids, Dietary Supplements. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Medical University in Lublin.
Abstract (Originalsprache)
Immunoglobulin A nephropathy (IgAN) is the most common glomerulonephritis worldwide. Xanthohumol (XN) exhibits anti‐inflammatory, anti‐oxidant, anti‐fibrotic, anti‐microbial, anti‐proliferative, and immunomodulatory effects that all are associated with the IgAN pathogenesis. Our study aims to evaluate the potential impact of XN on the clinical course of IgAN refractory to conventional treatment. Included were five rigorously selected IgAN patients with poor prognosis assessed on the basis of clinical findings and renal biopsy. Patients received XN orally at a daily dose of 2 mg/kg body weight. Biochemical tests were performed the day before the start of XN administration, and then after 2, 4, 12, 24, and 52 weeks of XN administration. XN induced a decrease in daily proteinuria in all patients. Compared to baseline values, at T52 the mean reduction in proteinuria and albumin‐creatinine‐ratio was 45.3% and 48.4% respectively ( p < 0.001 in both cases). Reduction of urine erythrocyturia occurred in four out of five patients. No progression of chronic kidney disease was observed in any patient. No adverse effects of XN were observed, and XN was well tolerated. XN supplementation has potential as an additive treatment for IgAN patients. Moreover, XN appears to be safe and well tolerated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Collegium Medicum, Department of Internal Medicine and Family Medicine, Jan Kochanowski University in Kielce, Kielce, Poland.
- Department of Nephrology, Regional Hospital of Stalowa Wola, Stalowa Wola, Poland.
- First Department of Anaesthesiology and Intensive Therapy, Medical University in Lublin, Lublin, Poland.
- Department of Cell Biology, Maria Curie-Sklodowska University, Akademicka 19, Lublin, Poland.
- Department of Pathology, Medical University of Warsaw, Warsaw, Poland.
- Department of Pharmaceutical Sciences and the Linus Pauling Institute, Oregon State University, Corvallis, Oregon, USA.
Förderung
- Medical University in Lublin
Zitieren
APA
Jaroszyński, A., Dabrowski, W., Gagoś, M., Perkowska-Ptasińska, A., & Stevens, J. F. (2026). Beneficial Effect of Xanthohumol Supplementation on the Clinical Course of IgA Nephropathy Refractory to Conventional Treatment—A Prospective, Open‐Label Case Series. Molecular Nutrition & Food Research, 70(6). https://doi.org/10.1002/mnfr.70439
Vancouver
Jaroszyński A, Dabrowski W, Gagoś M, Perkowska-Ptasińska A, Stevens JF. Beneficial Effect of Xanthohumol Supplementation on the Clinical Course of IgA Nephropathy Refractory to Conventional Treatment—A Prospective, Open‐Label Case Series. Molecular Nutrition & Food Research. 2026;70(6). doi:10.1002/mnfr.70439
BibTeX
@article{Jaroszyski2026,
author = {Jaroszyński, Andrzej and Dabrowski, Wojciech and Gagoś, Mariusz and Perkowska-Ptasińska, Agnieszka and Stevens, Jan F},
title = {Beneficial Effect of Xanthohumol Supplementation on the Clinical Course of IgA Nephropathy Refractory to Conventional Treatment—A Prospective, Open‐Label Case Series},
journal = {Molecular Nutrition & Food Research},
year = {2026},
volume = {70},
number = {6},
doi = {10.1002/mnfr.70439}
}
EUVIMED